Research programme: non-immunogenic factor VIII - Biotest AG/EpiVax

Drug Profile

Research programme: non-immunogenic factor VIII - Biotest AG/EpiVax

Alternative Names: Deimmunised FVIII-Tregitope

Latest Information Update: 24 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotest AG; EpiVax
  • Class Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Haemophilia

Most Recent Events

  • 24 Jul 2016 Early research is ongoing in Germany and USA
  • 04 Dec 2013 Early research in Haemophilia in Germany & USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top